<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45090">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01719926</url>
  </required_header>
  <id_info>
    <org_study_id>NL40487.041.12</org_study_id>
    <nct_id>NCT01719926</nct_id>
  </id_info>
  <brief_title>Phase I Platinum Based Chemotherapy Plus Indomethacin</brief_title>
  <acronym>PIFA</acronym>
  <official_title>Phase I Study Evaluating Indomethacin in Combination With Platinum-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mesenchymal stem cells (MSCs) are present in the circulation of cancer patients, and are
      recruited to the stroma of both the primary tumor and metastasis. Recent preclinical
      research has shown that in response to platinum-based chemotherapy, MSCs secrete two
      specific platinum-induced fatty acids (PIFAs) which induce resistance to a broad spectrum of
      chemotherapies. The secreted PIFAs are the fatty acid oxo-heptadecatetraenoic acid (KHT) and
      the omega-3 fatty acid hexadecatetraenoic acid (16:4). These PIFAs are produced via the
      COX-1 pathway. COX inhibitors, including indomethacin. This phase 1 study explores the
      safety of combining indomethacin with platinum containing chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Number of dose limiting toxicities at each dosage cohort</measure>
    <time_frame>From first dose of indomethacin until 28 days after last dose of indomethacin</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>During first 2 cycles of 3 weeks each</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum levels  of mesenchymal stem cells and platinum induced fatty acids at T = pre-chemotherapy, one, two and four hours expressed in pmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>From baseline to date of progressieve disease according RECIST 1.1, approximately 9 to 18 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy will be assessed according RECIST 1.1 criteria. Progression free survival is defined as time from baseline CT scan to progressive disease according RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Esophageal Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <arm_group>
    <arm_group_label>Capecitabine/Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving Capecitabine/Oxaliplatin chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin + Xeloda(Capecitabin) or Gemcitabin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving Cisplatin regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.</description>
    <arm_group_label>Capecitabine/Oxaliplatin</arm_group_label>
    <arm_group_label>Cisplatin + Xeloda(Capecitabin) or Gemcitabin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a histological proven malignancy receiving  cisplatin combined with
             gemcitabine or 5FU/capecitabine. (cisplatin dose range 60-80 mg/m2) (Arm I) or CAPOX
             (oxaliplatin, capecitabine) (Arm II) in a 21 day cycle.

          -  Age ≥ 18 years and &lt; 70 years.

          -  Platinum-based chemotherapy naïve for at least 6 months.

          -  Subjects with at least one evaluable lesion.

          -  WHO Performance Status of 0 or 1.

          -  Female participants should be of non-child bearing potential either physiologic or by
             using adequate contraception, have a negative serum pregnancy test, and refrain from
             breast feeding.

          -  Written informed consent.

        Exclusion Criteria:

          -  Known or suspected allergy or hypersensitivity to indomethacin or any agent given in
             association with this trial, in particular subjects who have a history of severe
             hypersensitivity reactions to anti-emetics (5-HT3 antagonists, metoclopramide or
             corticosteroids) and acetylsalicylic acid or other prostaglandin synthetase
             inhibitors.

          -  Symptomatic  brain or meningeal tumors

          -  Subjects with seizure disorder requiring medication (such as corticosteroids or
             anti-epileptics).

          -  Any of the following concurrent severe and/or uncontrolled medical conditions which
             could compromise participation in the study:

          -  Uncontrolled high blood pressure, history of labile hypertension, or history of poor
             compliance with an antihypertensive regimen

          -  Unstable angina pectoris

          -  Symptomatic congestive heart failure NYHA class ≥ 3 (see appendix 13.6)

          -  Myocardial infarction ≤ 6 months prior to randomization

          -  Serious uncontrolled cardiac arrhythmia

          -  Active peptic ulcer disease, gastritis, inflammatory bowel disease.

          -  History of active gastrointestinal bleeding

          -  History of cerebrovascular disease

          -  Bleeding diathesis

          -  Chronic renal disease defined as GFR (MDRD) &lt;60 ml/min

          -  Absolute Neutrophil Count (ANC) &lt; 1.5 x 109/L (&lt; 1500/mm3)

          -  Platelets (PLT) &lt; 100 x 109/L (&lt; 100,000/mm3)

          -  Hemoglobin (Hgb) &lt; 6.0 mmol/l (patients may be transfused to achieve adequate Hb)

          -  Partial thromboplastin time (PTT)  &gt; 1,5 x ULN

          -  Serum bilirubin &gt; 1.5 ULN

          -  Aspartate aminotransferase (AST/SGOT)  and alanine  aminotransferase (ALT/SGPT) &gt; 3.0
             x ULN (&gt; 5 x ULN if liver metastases present)

          -  Patients who are unable or unwilling to comply with the protocol

          -  Chronic treatment with a corticosteroid agent (nebulized corticosteroids are allowed)

          -  Patients who received radiation therapy within 4 weeks of the start of the study

          -  Patients who received an experimental agent less than 4 weeks before start of the
             study.

          -  Patients who used Omega-3/omega-6 containing products, including fish oil products
             less than 2 weeks before start of the study.

          -  Chronic use of NSAID's and/or acetylsalicylic acid and/or other prostaglandin
             synthetase inhibitors.

          -  Use of anticoagulant therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M.P.J.K. Lolkema, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>G.A. Cirkel, MD</last_name>
    <phone>+31 (0)88 75 55 555</phone>
    <phone_ext>4773</phone_ext>
    <email>g.a.cirkel-2@umcutrecht.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <state>Utrecht</state>
        <zip>3813TZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>H.j. Bloemendal, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>E.E. Voest, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>C. Sessa, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>October 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Martijn P. Lolkema</investigator_full_name>
    <investigator_title>MD/PhD</investigator_title>
  </responsible_party>
  <keyword>Colorectal</keyword>
  <keyword>Esophageal</keyword>
  <keyword>Indomethacin</keyword>
  <keyword>PIFA</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
